PROTALIX BIOTHERAPEUTICS, INC. (a Delaware corporation) 7,608,695 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 16th, 2021 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA is acting as representative (in such capacity, the “Representative”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 1,141,304 additional shares of Common Stock. The aforesaid 7,608,695 shares of Common Stock (the “Initial Securities”) to be purchased by the Underwriters a
